Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ANI Pharmaceuticals, Inc. - Common Stock
(NQ:
ANIP
)
72.83
-0.68 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ANI Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
February 24, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
January 24, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
From Mobile Clinics to Drug Development, This Company Is Attempting to Tackle Brain Disorders and Promote Mental Health Advances
↗
January 05, 2022
Photo by David Matos on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 03, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
↗
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP
December 21, 2021
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Mobile Clinics Featuring Novel Mental Health Treatments Reportedly Coming to Florida and Nevada
↗
December 20, 2021
Photo by Insung Yoon on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
7 of the Best Small-Cap Stocks to Buy Before 2022
↗
December 16, 2021
With 2021 coming to a close and a new year upon us, it's time to get a head start on some of the best small-cap stocks to buy.
Via
InvestorPlace
This Biotech Company Specializing in Brain Disorder Treatments Reports a Stronger Cash Position
↗
December 13, 2021
Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
November 22, 2021
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021
November 22, 2021
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
November 11, 2021
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
November 08, 2021
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
November 03, 2021
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
November 03, 2021
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
↗
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021
↗
November 02, 2021
Upgrades UBS upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
64 Biggest Movers From Yesterday
↗
November 02, 2021
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on...
Via
Benzinga
ANI Pharmaceuticals, inc (ANIP) Q3 2021 Earnings Call Transcript
↗
November 01, 2021
ANIP earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
ANI Pharma's Purified Cortrophin Gel Scores FDA Approval; Q3 Earnings Beat Estimates
↗
November 01, 2021
ANI Pharmaceuticals Inc (NASDAQ: ANIP) has reported Q3 sales of $52.1 million, down 1.7% Y/Y, better than the consensus of $49.70 million. The company achieved an...
Via
Benzinga
Topics
Earnings
Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide
↗
November 01, 2021
Toward the end of trading Monday, the Dow traded up 0.12% to 35,863.70 while the NASDAQ rose 0.18% to 15,525.52. The S&P, however, fell 0.10% to 4,600.81. The U.S. has the...
Via
Benzinga
Topics
Stocks
Dow, SPX Fall From Record Intraday Highs
↗
November 01, 2021
Stocks are mixed at midday, with the Dow Jones Industrial Average reversing some of this morning's gains after briefly toppling the 36,000 level for the first time ever.
Via
Talk Markets
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 01, 2021
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's regular session. As of 12:30 EST, this security is trading at a volume...
Via
Benzinga
Here's Why Ani Pharmaceuticals Stock Is Rocketing Higher Today
↗
November 01, 2021
The company reported positive third-quarter earnings, and the FDA granted approval for its generic version of Acthar Gel.
Via
The Motley Fool
Topics
Bankruptcy
Lawsuit
Mid-Day Market Update: Dow Rises 50 Points; ANI Pharmaceuticals Shares Jump
↗
November 01, 2021
Midway through trading Monday, the Dow traded up 0.14% to 35,871.27 while the NASDAQ rose 0.23% to 15,534.49. The S&P also fell, dropping 0.03% to 4,603.98. The U.S. has the...
Via
Benzinga
Topics
Stocks
Ani Pharma Rockets After Winning FDA Approval To Revive Old Merck Drug
↗
November 01, 2021
Cortophin Gel gained approval to treat several autoimmune conditions.
Via
Investor's Business Daily
40 Stocks Moving In Monday's Mid-Day Session
↗
November 01, 2021
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 250% to $8.91 on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the...
Via
Benzinga
ANI Pharmaceuticals's Return On Capital Employed Overview
↗
November 01, 2021
According to Benzinga Pro data, during Q3, ANI Pharmaceuticals (NASDAQ:ANIP) posted sales of $52.06 million. Earnings were up 77.1%, but ANI Pharmaceuticals still reported an...
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; PG&E Earnings Miss views
↗
November 01, 2021
Following the market opening Monday, the Dow traded up 0.08% to 35,846.72 while the NASDAQ rose 0.18% to 15,527.04. The S&P also fell, dropping 0.07% to 4,602.32. The U.S. has...
Via
Benzinga
Topics
Earnings
Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 01, 2021
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.